Sera Prognostics, Atreca spike after Baker Bros investments

Aslan Alphan Shares of Sera Prognostics ( NASDAQ: SERA ) and Atreca ( NASDAQ: BCEL ) traded higher on Thursday after hedge fund manager Baker Bros. Advisors disclosed investments in the companies. According to 13G filings on Wednesday, the New York based financial services firm has disclosed a passive stake of ~18% in Sera Prognostics ( SERA ), a Salt Lake City, Utah based diagnostics firm focused on women's health.

Another SEC filing from Atreca ( BCEL ) indicated that Baker Bros.'s investment in the immunotherapy developer rose to ~20%, or ~7.7M shares , up from ~3.5M. The San Carlos, California based nano cap biotech develops antibody based drugs for cancer. According to other 13G reports filed by Baker Bros.

on Wednesday, it has increased its stakes in Kymera Therapeutics ( KYMR ) and Replimune ( REPL ) to ~11% and ~16% , respectively. More on Atreca, Sera Prognostics, etc. Sera Prognostics: The Pregnancy Company On A Hot Streak Sera Prognostics, Inc (SERA) Q3 2023 Earnings Call Transcript Biggest stock movers today: Google, AMD, GameStop, C3.AI, Chewy and more Sera Prognostics shares rocket 160% on PreTRM study update Seeking Alpha’s Quant Rating on Atreca.